Judah Frommer

Q: What is Judah Frommer's success rate?

Judah Frommer currently has a success rate of 86.86273207800912.

Q: What is the average return of Judah Frommer's calls?

Their stock ratings have generated an average return of 28.337912971810866.

Morgan Stanley | Healthcare

Judah Frommer is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1076 out of 4559 analysts, they have issued 16 stock ratings with a success rate of 86.86% and an average return of 28.34%.

With 16 ratings to date, Judah Frommer is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 86.86% and an average return of 28.34%, highlighting promising potential as their track record develops further.

#1076

Out of 4559

Total Ratings

+86.86%

Success Rate

+28.34%

Average Return

Recent Ratings Analysis

BLTE

Buy

Mar 03, 2026

Target

$201.00

Current

$167.88

Performance

0.00%

Judah Frommer rated BLTE as Overweight on Mar 03, 2026, setting a price target of 201. Shares have remained stable near 167.88, leaving the 201 target still in play.

AGMB

Buy

Mar 03, 2026

Target

$28.00

Current

$15.90

Performance

0.00%

On Mar 03, 2026, AGMB was given a Overweight rating by Judah Frommer, with a target price of 28. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

GMAB

Hold

Feb 16, 2026

Target

$34.00

Current

$27.66

Performance

GMAB received a Equal-Weight rating from Judah Frommer on Feb 16, 2026, aiming for 34. Shares remained flat at 27.66, aligning with the neutral rating.

RGNX

Buy

Feb 10, 2026

Target

$25.00

Current

$8.69

Performance

-1.81%

On Feb 10, 2026, Judah Frommer published a Overweight outlook on RGNX, with a target of 25. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 8.69.

ABVX

Buy

Jan 09, 2026

Target

$145.00

Current

$111.10

Performance

-2.88%

Judah Frommer on Jan 09, 2026 assigned ABVX a Overweight rating, with a price target of 145. The recommendation remains pending validation as shares consolidate around 111.1.

ZBIO

Hold

Jan 06, 2026

Target

$37.00

Current

$25.18

Performance

65.66%

On Jan 06, 2026, Judah Frommer reaffirmed ZBIO with a Equal-Weight rating, targeting 37. Market strength beyond 25.18 went further than the conservative outlook suggested.

EVMN

Buy

Dec 01, 2025

Target

$36.00

Current

$23.88

Performance

14.20%

EVMN was rated Overweight by Judah Frommer on Dec 01, 2025, with a price objective of 36. A bullish response from the market helped close the gap of 12.12 to the target.

TRVI

Buy

Nov 14, 2025

Target

$19.00

Current

$12.26

Performance

7.83%

On Nov 14, 2025, Judah Frommer initiated coverage on TRVI with a Overweight rating and target of 19. The stock’s climb of 7.83% since the call highlights the foresight in the rating.

APLS

Hold

Jul 02, 2025

Target

$26.00

Current

$20.16

Performance

13.13%

Judah Frommer issued a Equal-Weight recommendation for APLS on Jul 02, 2025, price target set at 26. A neutral call gave way to stronger-than-expected performance, closing in on 26.

BPMC

Hold

Jun 05, 2025

Target

$129.00

Current

$129.46

Performance

1.22%

On Jun 05, 2025, BPMC was evaluated by Judah Frommer, who gave a Equal-Weight rating and target of 129. Hold sentiment was validated by subdued trading with no breakout beyond 129.46.

CLDX

Buy

Mar 20, 2025

Target

$46.00

Current

$28.94

Performance

45.57%

Judah Frommer rated CLDX as Overweight on Mar 20, 2025, setting a price target of 46. The call has proven timely, with shares rising 45.57% toward the price target of 46.

GLPG

Sell

Feb 14, 2025

Target

$22.00

Current

$33.05

Performance

29.91%

On Feb 14, 2025, GLPG was given a Underweight rating by Judah Frommer, with a target price of 22. The Sell stance aligned with downward action, with the stock sliding from 33.05 to 33.05.

FDMT

Sell

Jan 13, 2025

Target

$6.00

Current

$8.46

Performance

77.73%

FDMT received a Underweight rating from Judah Frommer on Jan 13, 2025, aiming for 6. Shares declined 77.73%, matching the cautious outlook.

BCAX

Buy

Oct 08, 2024

Target

$35.00

Current

$17.92

Performance

-20.53%

On Oct 08, 2024, Judah Frommer published a Overweight outlook on BCAX, with a target of 35. Market action contradicted the Buy thesis, as shares slipped to 17.92.

Frequency Asked Questions

Who is Judah Frommer?

Judah Frommer is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Judah Frommer's success rate?

Judah Frommer currently has a success rate of +86.86%.

How many ratings has Judah Frommer issued?

Judah Frommer has issued 16 stock ratings so far.

What is the average return of Judah Frommer's calls?

Their stock ratings have generated an average return of +28.34%.

What is Judah Frommer's ranking?

Judah Frommer is ranked #1076 out of 4559 analysts.

What types of ratings does Judah Frommer give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Judah Frommer?

You can follow Judah Frommer by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Judah Frommer?

Their latest rating was a Buy on BLTE issued on 2026-03-03.